Episode 35. Bispecific Antibodies in Lymphoma with Dr. Michael Dickinson
Blood Cancer Talks · Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed:
1. Glofitamab for Relapsed/Refractory DLBCL:
https://pubmed.ncbi.nlm.nih.gov/36507690/
2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:
https://pubmed.ncbi.nlm.nih.gov/31451445/
3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:
https://pubmed.ncbi.nlm.nih.gov/36548927/
4. Phase 2 trial of mosunetuzumab in relapsed/refractory follicular lymphoma:
https://pubmed.ncbi.nlm.nih.gov/35803286/
5. Phase 1 trial of odronextamab in relapsed/refractory B-cell NHL:
https://pubmed.ncbi.nlm.nih.gov/35366963/
6. Epcoritamab + R2 in high-risk follicular lymphoma:
https://meetings.asco.org/abstracts-presentations/218265
7. Glofitamab in Mantle Cell Lymphoma:
https://ashpublications.org/blood/article/140/Supplement%201/178/489039